Medical Affairs Consulting
Medical affairs consulting helps pharmaceutical and biotech companies turn scientific evidence into clinical impact. Speyside Health begins by understanding the landscape and its stakeholders in depth, then builds the strategy, and the surrounding ecosystem, that carries a programme or a new treatment from scientific rationale to adoption in practice, supporting implementation and the breadth of activity that real uptake requires.
Our medical affairs services
We work across the therapeutic landscape, with documented depth in the areas below. Each groups the specific conditions our teams have delivered on:
Medical and scientific strategy
connecting global medical objectives to local execution across the product lifecycle, market by market, including regional and local medical strategy adaptation.
Scientific narrative and messaging
translating clinical evidence into locally relevant medical stories, and identifying unmet need, care-pathway friction and evidence gaps.
Expert and stakeholder engagement
KOL, HCP and patient-advocacy strategy; advisory boards, steering committees, consensus meetings and expert roundtables (KOLs, policy, patients and multidisciplinary teams).
Scientific exchange and publications
publication planning, scientific exchange, congress support, and medical education materials and educational programmes.
Evidence planning and dissemination
RWE and HEOR planning and evidence dissemination to meet the requirements of regulators, payers and clinicians.
Scientific and medical communications
accurate, compliant medical content across audiences and channels.
How do we build KOL and stakeholder engagement in complex markets?
We start from a structured stakeholder architecture, who to engage, through which tactics, at which lifecycle stage, validated by in-country consultants rather than desk research alone. Mapping goes beyond the obvious names: we dig deeper to surface the hidden connections and informal influence between stakeholders, so that every potential advocacy pathway is considered, not only the visible ones. And we work to understand the evidence each party actually needs, clinical, regulatory, payer and patient, so engagement is built on what will move each decision. Plans are measured on uptake and impact, changes in clinical practice, guidelines and access, not activity counts.
FAQ
in Central & Eastern Europe since the mid-1990s; operational across 19 countries spanning the EU5, CEE, Russia and Eurasia.
EU5
CEE
Russia
Eurasia
19 countries
Regional hubs in India and Singapore, with team members on the ground in fifteen countries from China to Australia.
India
Singapore
China
Australia
15 countries
Offices in Brazil, Mexico and Colombia, supported by consultants and affiliates across Central & South America and the Caribbean.
Brazil
Mexico
Colombia
Caribbean
Led from Saudi Arabia with capability across all GCC markets, serving public and private sector clients.
Saudi Arabia
GCC
Overseen from hub offices in South Africa, Kenya and Nigeria, with reach across the continent.
South Africa
Kenya
Nigeria
Our core team
Senior people, named and accountable, clients work with the people on this page, supported by an extended network of vetted in-market consultants and key experts across 40+ countries.
IH
Ian Herbison
CEO & Head of Healthcare
Over the last 25 years Ian has led international policy programs for many leading healthcare multinationals. During this time, he has lived, built and managed teams across Central & Eastern Europe, Latin America and Asia Pacific. In recent years he has focused on global & regional counsel to set policy strategy and frameworks.
Simonetta Ballali
Deputy Head of Healthcare, Medical Affairs Director
Connects stakeholder-specific streams into a strategic thread that drives change in clinical practice. Joined from IQVIA, where she led the Medical Affairs Communications Practice.
JV
Dr Julieta Villega
LATAM Healthcare Practice Lead
Medical doctor and clinical epidemiologist with over 12 years of experience in health policy and healthcare strategy across Latin America.
DT
Danielle Todesco
Senior Consultant, Healthcare Practice
Public policy specialist with 5+ years across ASEAN, leading health-policy projects and advocacy for multinational clients.
Therapeutic areas: where we go deep
We work across the therapeutic landscape, with documented depth in the areas below. Each groups the specific conditions our teams have delivered on:
01
Rare diseases
spinal muscular atrophy (SMA) and gene therapies, pulmonary arterial hypertension (PAH), haemophilia.
02
Oncology
lung, breast, prostate, melanoma, hepatocellular carcinoma (HCC / liver), and cell & gene therapies.
03
Immunology
-
04
Non-communicable diseases
cardiovascular disease and lipid management, ischemic stroke, diabetes and cardiorenal, chronic kidney disease (CKD), COPD and respiratory.
05
Women's health
maternal and neonatal health.
06
Infectious diseases
HIV & viral hepatitis, vaccines (RSV, COVID-19).
07
Consumer health
self-care / OTC.
08
Nutrition
clinical nutrition
09
Diagnostics & MedTech
-
Talk to us about the landscape you are trying to change.
@speyside-group.com